TOday’s Movers: Merck \u0026 Co (NYSE:MRK) Stock Rating Reconfirmed by Barclays; $75 Target Price Indicates 7.65 % Potential

September 8, 2018 - By Megan Stone

Merck & Co., Inc. (NYSE:MRK) Logo

Investors sentiment increased to 1 in Q1 2018. Its up 0.06, from 0.94 in 2017Q4. It increased, as 72 investors sold Merck & Co., Inc. shares while 603 reduced holdings. 114 funds opened positions while 561 raised stakes. 1.91 billion shares or 1.08% less from 1.93 billion shares in 2017Q4 were reported.

Front Barnett Associate Llc holds 0.04% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 3,953 shares. Ashfield Cap Prtn Ltd Llc stated it has 81,406 shares or 0.58% of all its holdings. Guggenheim Ltd accumulated 0.21% or 1.61M shares. Botty Lc has invested 0.92% of its portfolio in Merck & Co., Inc. (NYSE:MRK). State Bank Of America De owns 0.42% invested in Merck & Co., Inc. (NYSE:MRK) for 45.09M shares. Bancshares Of Nova Scotia Trust holds 0.21% or 33,629 shares in its portfolio. Wealthtrust holds 0.07% in Merck & Co., Inc. (NYSE:MRK) or 2,495 shares. Fairfield Bush accumulated 13,489 shares. First Manhattan stated it has 213,274 shares. Putnam reported 4.53M shares or 0.57% of all its holdings. Advisory Network Lc stated it has 0.24% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Moreover, Elm Advisors Limited Liability Company has 0.44% invested in Merck & Co., Inc. (NYSE:MRK) for 10,471 shares. Moreover, Headinvest Ltd Com has 0.45% invested in Merck & Co., Inc. (NYSE:MRK) for 25,820 shares. 16,628 are owned by Lincoln National. First Republic Invest Incorporated reported 1.03 million shares stake.

Merck \u0026 Co (NYSE:MRK) Rating Reaffirmed

Barclays now has a $75 target price per share on shares of Merck \u0026 Co (NYSE:MRK). The target price per share indicates a potential upside of 7.65 % from the current price of Merck \u0026 Co (NYSE:MRK). This rating was disclosed to clients in an analyst report on Friday morning.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 9 analysts covering Merck & Company (NYSE:MRK), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Merck & Company has $74 highest and $5500 lowest target. $69’s average target is -0.96% below currents $69.67 stock price. Merck & Company had 12 analyst reports since March 12, 2018 according to SRatingsIntel. Guggenheim maintained the shares of MRK in report on Tuesday, April 17 with “Buy” rating. On Tuesday, April 17 the stock rating was upgraded by Morgan Stanley to “Overweight”. The firm earned “Hold” rating on Friday, March 23 by Jefferies. Goldman Sachs upgraded Merck & Co., Inc. (NYSE:MRK) on Monday, April 23 to “Buy” rating. The company was maintained on Friday, April 20 by Cowen & Co. Bank of America maintained the shares of MRK in report on Monday, July 30 with “Buy” rating. The rating was maintained by Bank of America on Tuesday, April 17 with “Buy”. On Friday, April 13 the stock rating was maintained by Jefferies with “Hold”. The stock of Merck & Co., Inc. (NYSE:MRK) has “Overweight” rating given on Thursday, April 5 by Barclays Capital. Leerink Swann upgraded Merck & Co., Inc. (NYSE:MRK) on Monday, March 12 to “Buy” rating.

The stock increased 0.42% or $0.29 during the last trading session, reaching $69.67. About 9.52 million shares traded or 10.50% up from the average. Merck & Co., Inc. (NYSE:MRK) has declined 9.15% since September 8, 2017 and is downtrending. It has underperformed by 21.72% the S&P500.

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on October, 26. They expect $1.15 earnings per share, up 3.60 % or $0.04 from last year’s $1.11 per share. MRK’s profit will be $3.06B for 15.15 P/E if the $1.15 EPS becomes a reality. After $1.06 actual earnings per share reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts 8.49 % EPS growth.

Merck & Co., Inc. provides healthcare solutions worldwide. The company has market cap of $185.29 billion. It operates in four divisions: Pharmaceutical, Animal Health, Healthcare Services, and Alliances divisions. It has a 143.65 P/E ratio. The firm offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

More important recent Merck & Co., Inc. (NYSE:MRK) news were published by: 247Wallst.com which released: “Boeing, Visa Prop Up the Dow Thursday” on September 06, 2018, also Benzinga.com published article titled: “Health Care Has Been On Fire. Will The Uptrend Continue?”, Benzinga.com published: “Incyte Has Quietly Risen 13 Percent In The Last Two Weeks, And That Uptrend Looks Like It Will Continue” on August 21, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) was released by: Seekingalpha.com and their article: “Pfizer: Pipeline Will Easily Offset Patent Expirations” with publication date: September 04, 2018.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.